Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | AKT1 | P31749 | 12/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2697706 | 0.87 | ALDH1A1 (0.50) | ALDH1A1AKT1CYP1A2SMN1; SMN2LMNA | |
| SCHEMBL2699187 | 0.87 | AKT1 (0.48) | ALDH1A1AKT1LMNATHRB | |
| SCHEMBL9431569 | 0.85 | ALDH1A1 (0.57) | ALDH1A1AKT1CYP1A2SMN1; SMN2 | |
| SCHEMBL2700690 | 0.84 | AKT1 (0.52) | ALDH1A1AKT1 | |
| SCHEMBL2700153 | 0.84 | SMN1; SMN2 (0.59) | ALDH1A1AKT1CYP1A2SMN1; SMN2 | |
| SCHEMBL9684779 | 0.82 | ALDH1A1 (0.52) | ALDH1A1AKT1CYP1A2SMN1; SMN2 | |
| SCHEMBL2700613 | 0.82 | ALDH1A1 (0.50) | ALDH1A1AKT1SMN1; SMN2MAPT | |
| SCHEMBL9680558 | 0.78 | EGFR (0.56) | ALDH1A1AKT1CYP1A2SMN1; SMN2MAPT | |
| SCHEMBL11486350 | 0.77 | ALDH1A1 (0.55) | ALDH1A1AKT1CYP1A2SMN1; SMN2 | |
| SCHEMBL8790081 | 0.75 | ALDH1A1 (0.71) | ALDH1A1AKT1CYP1A2SMN1; SMN2IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569331-B2 | Substituted benzo[f]lmidazo[1,2-d]pyrido[2,3-b][1,4]diazepine compounds | ARQULE, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120108574-A1 | Substituted Benzo-Imidazo-Pyrido-Diazepine Compounds | ARQULE, INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108574-A1 | Substituted Benzo-Imidazo-Pyrido-Diazepine Compounds | BRD4, BRPF3, BRD3 | ALDH1A1 1178/4885AKT1 3524/4885CYP1A2 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.